Pharmaceuticals Brazil

Brazil Compounded Weight Loss Medications Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Brazil Compounded Weight Loss Medications Market Industry Trends and Forecast to 2034: Segmented by (Drug, Channel, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Brazil · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $36.8 Mn Placeholder estimate
Estimate 2025 $41.6 Mn 2.4% of the global market
Projected 2034 $125.0 Mn 200.4% Adds $83.4 Mn over 9 forecast years
CAGR 2025–2034 13.0% Faster than 68% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Brazil is 2.37% of the global market.
  • In Latin America, the largest is Brazil (this report) at $41.6 Mn.
  • Fastest growing: Brazil (this report) at 13% a year.
  • Brazil ranks 1st of 3 by size in Latin America.

Market size projection

Brazil

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$83.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Compounded Weight Loss Medications Market market size by year, Brazil
YearMarket sizeChange that yearSince 2025
2024 (estimate) $36.8 Mn — —
2025 (base) $41.6 Mn +$4.8 Mn —
2026 (forecast) $47.0 Mn +$5.4 Mn +13%
2027 (forecast) $53.2 Mn +$6.1 Mn +27.7%
2028 (forecast) $60.1 Mn +$6.9 Mn +44.3%
2029 (forecast) $67.9 Mn +$7.8 Mn +63%
2030 (forecast) $76.7 Mn +$8.8 Mn +84.2%
2031 (forecast) $86.7 Mn +$10.0 Mn +108.2%
2032 (forecast) $97.9 Mn +$11.3 Mn +135.3%
2033 (forecast) $110.7 Mn +$12.7 Mn +165.8%
2034 (forecast) $125.0 Mn +$14.4 Mn +200.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.76 Bn
  2. North America $927.2 Mn
  3. US $819.7 Mn
  4. Europe $373.8 Mn
  5. APAC $367.0 Mn
  6. China $151.5 Mn
  7. Canada $144.4 Mn
  8. Japan $119.6 Mn
  9. Latin America $77.3 Mn
  10. Germany $68.9 Mn
  11. Middle East $61.0 Mn
  12. UK $49.9 Mn
  13. France $46.2 Mn
  14. Brazil (this report) $41.6 Mn
  15. Italy $38.5 Mn
  16. Spain $34.9 Mn
  17. Saudi Arabia $35.2 Mn
  18. Ecuador $34.0 Mn
  19. Africa $29.6 Mn
  20. India $29.1 Mn
  21. Mexico $22.7 Mn
  22. Australia $21.6 Mn
  23. Russia $19.0 Mn
  24. New Zealand $15.4 Mn
  25. South Africa $12.8 Mn
  26. UAE $9.9 Mn
  27. Egypt $5.7 Mn
  28. Philippines $3.7 Mn
  29. Hong Kong $2.7 Mn
  30. Malaysia $2.5 Mn
  31. Singapore $2.3 Mn
  32. Thailand $1.9 Mn
  33. Kenya $1.2 Mn

Report snapshot

Brazil Compounded Weight Loss Medications Market Analysis at a glance
Market size, 2025$41.6 Mn placeholder estimate
Forecast, 2034$125.0 Mn placeholder estimate
Growth (CAGR), 2025–203413.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, channel and end user (see all)
Key playersHims & Hers Health, Ro, Empower Pharmacy, Noom, WeightWatchers (see all)
Regulator in BrazilANVISASource: ANVISA. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Brazil Compounded Weight Loss Medications Market Analysis Executive Summary

Compounded weight loss medications are pharmacy-prepared versions of weight-loss drugs, made for individual patients, often during shortages of branded products.

Key segments of the compounded Weight Loss Medications market include drug (Compounded Semaglutide, Compounded Tirzepatide and Others) and channel (Compounding Pharmacies, Telehealth Platforms and Clinics).

Bar chart: Brazil Compounded Weight Loss Medications market size, 2024–2034, placeholder estimates. $36.8 Mn in 2024, $41.6 Mn in 2025 and $125.0 Mn in 2034, 13.0% CAGR.
Brazil Compounded Weight Loss Medications market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Brazil Compounded Weight Loss Medications Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the compounded Weight Loss Medications market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the compounded Weight Loss Medications market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Compounded Weight Loss Medications Market in Brazil

The compounded Weight Loss Medications market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Compounded Weight Loss Medications Market in Brazil

Compounded Weight Loss Medications in Brazil: rules, payment and health figures

Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale.⁠[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.⁠[2] Obesity (adults): 30.1% of adults in 2024, the latest WHO figure for Brazil.⁠[3]

[1] ANVISA. Checked 14 Nov 2026.

[2] CONITEC. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for compounded Weight Loss Medications. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Brazil.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Compounded Weight Loss Medications right now, from free public sources.

Latest research 9 papers since 2021 (worldwide)

  1. Compounded GLP-1 Dispensing Patterns and Vitamin B12 Coformulation. JAMA, 2026
  2. Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand. JAMA health forum, 2026
  3. Angioedema After Accidental Semaglutide Dosing Error: A Case Report. Journal of clinical medicine, 2026
  4. Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. Pharmacoepidemiology and drug safety, 2025
  5. Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend. Journal of the Endocrine Society, 2025
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Compounded Weight Loss Medications in context

Brazil compared

  • Obesity (adults): 30.1% of adults (2024). World: 16.2% of adults (2024). 2nd highest of the 4 countries we cover in Latin America.[1]
  • Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[2]
  • Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[3]

[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Compounded Weight Loss Medications market in Brazil?
Placeholder estimate: about $41.6 Mn in 2025, rising to about $125.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Compounded Weight Loss Medications market in Brazil growing?
Placeholder estimate: about 13.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Compounded Weight Loss Medications market report cover?
The report splits the market by drug (Compounded Semaglutide, Compounded Tirzepatide, Others), channel (Compounding Pharmacies, Telehealth Platforms, Clinics) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Compounded Weight Loss Medications market?
Key players include Hims & Hers Health, Ro, Empower Pharmacy, Noom and WeightWatchers.
What is driving the Compounded Weight Loss Medications market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the compounded Weight Loss Medications market.
Who regulates Compounded Weight Loss Medications in Brazil?
Medicines need registration with ANVISA, the National Health Surveillance Agency, before sale. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
What does WHO report for Brazil?
Obesity (adults): 30.1% of adults in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 15 Nov 2026.
How many people in Brazil are 65 or older?
11.5% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
How much research is published on Compounded Weight Loss Medications?
PubMed lists 9 papers on Compounded Weight Loss Medications added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Compounded Weight Loss Medications in Brazil? Our analysts can size it for your plan. Talk to us See the public data Obesity (adults) for every country, free. Open the Public Health Dashboard

From our blog

Weight Management Supplements in the GLP-1 Era2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack… Snoring and Sleep Apnoea Devices: Sleeping BetterAn estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral… Diabetes Medicines: How Treatment Choices Are ChangingWHO counts 830 million people with diabetes, and 59% of adults with diabetes took no medicine for it in 2022…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Brazil

See all
Same topic, other categories

Related on obesity and pharmacy and generics

See the topic